Topiramate

Topiramate · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 16, 2027

~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (70)

Aug 21, 2040method-of-use (U-3415)US 11433046
Aug 21, 2040formulationUS 11633374
Aug 21, 2040formulationUS 11826343
Aug 21, 2040formulationUS 11911362
Aug 21, 2040formulationUS 12290503
Mar 19, 2033method-of-use (U-766)US 10363224
Mar 19, 2033method-of-use (U-766)US 10363224
Mar 19, 2033method-of-use (U-766)US 10363224
Mar 19, 2033method-of-use (U-766)US 10363224
Mar 19, 2033method-of-use (U-766)US 10363224
Mar 19, 2033formulationUS 8652527
Mar 19, 2033formulationUS 8652527
Mar 19, 2033formulationUS 8652527
Mar 19, 2033formulationUS 8652527
Mar 19, 2033formulationUS 8652527
Mar 19, 2033formulationUS 8889190
Mar 19, 2033formulationUS 8889190
Mar 19, 2033formulationUS 8889190
Mar 19, 2033formulationUS 8889190
Mar 19, 2033formulationUS 8889190
Mar 19, 2033formulationUS 9101545
Mar 19, 2033formulationUS 9101545
Mar 19, 2033formulationUS 9101545
Mar 19, 2033formulationUS 9101545
Mar 19, 2033formulationUS 9101545
Mar 19, 2033formulationUS 9555005
Mar 19, 2033formulationUS 9555005
Mar 19, 2033formulationUS 9555005
Mar 19, 2033formulationUS 9555005
Mar 19, 2033formulationUS 9555005
Apr 4, 2028formulationUS 82985761.7y
Apr 4, 2028formulationUS 82985761.7y
Apr 4, 2028formulationUS 82985761.7y
Apr 4, 2028formulationUS 82985761.7y
Nov 16, 2027formulationUS 103147901.4y
Nov 16, 2027formulationUS 103147901.4y
Nov 16, 2027formulationUS 103147901.4y
Nov 16, 2027formulationUS 103147901.4y
Nov 16, 2027formulationUS 82985801.4y
Nov 16, 2027formulationUS 82985801.4y
Nov 16, 2027formulationUS 82985801.4y
Nov 16, 2027formulationUS 82985801.4y
Nov 16, 2027formulationUS 86636831.4y
Nov 16, 2027formulationUS 86636831.4y
Nov 16, 2027formulationUS 86636831.4y
Nov 16, 2027formulationUS 86636831.4y
Nov 16, 2027formulationUS 88772481.4y
Nov 16, 2027formulationUS 88772481.4y
Nov 16, 2027formulationUS 88772481.4y
Nov 16, 2027formulationUS 88772481.4y
Nov 16, 2027method-of-use (U-106)US 88891911.4y
Nov 16, 2027method-of-use (U-1992)US 88891911.4y
Nov 16, 2027method-of-use (U-1992)US 88891911.4y
Nov 16, 2027method-of-use (U-1992)US 88891911.4y
Nov 16, 2027formulationUS 89929891.4y
Nov 16, 2027formulationUS 89929891.4y
Nov 16, 2027formulationUS 89929891.4y
Nov 16, 2027formulationUS 89929891.4y
Nov 16, 2027formulationUS 95499401.4y
Nov 16, 2027formulationUS 95499401.4y
Nov 16, 2027formulationUS 95499401.4y
Nov 16, 2027formulationUS 95499401.4y
Nov 16, 2027formulationUS 95550041.4y
Nov 16, 2027formulationUS 95550041.4y
Nov 16, 2027formulationUS 95550041.4y
Nov 16, 2027formulationUS 95550041.4y
Nov 16, 2027formulationUS 96229831.4y
Nov 16, 2027formulationUS 96229831.4y
Nov 16, 2027formulationUS 96229831.4y
Nov 16, 2027formulationUS 96229831.4y

FDA exclusivities (2)

Feb 1, 2026CGTCGT
Jan 5, 2026PCPC

topiramate ER

indications

all catalysts(62)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (70)

FDA exclusivities (2)

🐶 often sniffed alongside

Trials studying topiramate ER